天津市武清区龙济医院路公交车路线天津省天津市龙济的口碑,阳痿治疗天津武清区龙济医院男科,武清龙济门诊部好不好,武清男科医院排名天津武清龙济医院,天津市龙济是治疗男科的嘛,龙济医院性功能,龙济秘尿外科医院怎么样

WASHINGTON, May 27 (Xinhua) -- The U.S. Treasury Department said in a report released on Friday that China was not manipulating its currency."In China, since the authorities decided in June 2010 to allow the exchange rate to appreciate in response to market forces, the renminbi (RMB) has appreciated by a total of 5.1 percent against the dollar in nominal terms through the end of April 2011, or at an annual pace of approximately 6.0 percent," noted the semi- annual report on international economic and exchange rate policies.The Treasury said that as inflation in China is significantly higher than it is in the United States, the renminbi has appreciated more rapidly against the dollar on a real, inflation- adjusted basis, at a rate of around 9 percent per year.The delayed report, which was originally scheduled to be sent to the Congress on April 15, finds "no major trading partner of the United States" manipulated its currency during the period covered in the report.The Treasury added that it will continue to "closely monitor" the renminbi appreciation pace.The report also noted that the U.S. economy is recovering from its deepest recession in the post-war period."While recent growth is encouraging, the economy still faces significant challenges," said the report. The number one challenge is still in the labor market.The U.S. unemployment rate, currently at 9.0 percent, is not expected to fall significantly this year.Besides, housing market and long-term fiscal position are " unsustainable," according to the report.In recent remarks, Treasury Secretary Timothy Geithner stated that China is the fastest growing market for U.S. exports. In 2010, U.S. exports to China grew at a pace that was 50 percent higher than the rest of the world.

LOS ANGELES, April 2 (Xinhua) -- People taking antidepressants may be more likely to develop thicker arteries which may raise the risk of heart disease and stroke, a new study suggests.Depression can heighten the risk for heart disease, but the effect of antidepressant use is separate and independent from depression itself, according to the study make public by the American Association for the Advancement of Science (AAAS) on Saturday.The data suggest that antidepressants may combine with depression for a negative effect on blood vessels, said study first author Amit Shah, MD, a cardiology fellow at Emory University School of Medicine.Study findings will be presented on April 5 at the American College of Cardiology meeting in New Orleans, according to the AAAS.The study included 513 middle-aged male twins who both served in the U.S. military during the Vietnam War. Twins are genetically the same but may be different when it comes to other risk factors such as diet, smoking and exercise, so studying them is a good way to distill out the effects of genetics.Researchers measured carotid intima-media thickness - the thickness of the lining of the main arteries in the neck -- by ultrasound. Among the 59 pairs of twins where only one brother took antidepressants, the one taking the drugs tended to have higher carotid intima-media thickness (IMT), even when standard heart disease risk factors were taken into account.The effect was seen both in twins with or without a previous heart attack or stroke. A higher level of depressive symptoms was associated with higher IMT only in those taking antidepressants."One of the strongest and best-studied factors that thickens someone's arteries is age, and that happens at around 10 microns per year," Shah said. "In our study, users of antidepressants see an average 40 micron increase in IMT, so their carotid arteries are in effect four years older."Antidepressants' effects on blood vessels may come from changes in serotonin, a chemical that helps some brain cells communicate but also functions outside the brain, Shah said."I think we have to keep an open mind about the effects of antidepressants on neurochemicals like serotonin in places outside the brain, such as the vasculature. The body often compensates over time for drugs' immediate effects," Shah said. " Antidepressants have a clinical benefit that has been established, so nobody taking these medications should stop based only on these results. This isn 't the kind of study where we can know cause and effect, let alone mechanism, and we need to see whether this holds up in other population groups."

BEIJING, May 4 (Xinhuanet) -- Children with autism have slightly bigger brains than children without the condition, a study suggests.The research published in the May issue of Archives of General Psychiatry noted the difference in the brain size appears related to increased rates of brain growth before age 2.The researchers from the University of North Carolina also pointed out that though the enlargement continues, the increased growth does not.In 2005, the researchers studied a group of 2-year-old children, and found out the ones with autism had brains that were 5% to 10% larger than children without it.Now the researchers assessed the same group of children at age 5, the psychiatrists re-scanned the brains of 38 children with autism and 21 without the condition. The autistic children still had slightly larger brains, but they had grown at the same rate as the comparison group.This finding could lead to a better understanding of the genes that drive autism, which, in turn, could lead to earlier identification and treatment of the disorder, said study researcher Joseph Piven, MD, according to media report.

BEIJING, Feb. 18 (Xinhua) -- In the next five years, China will further expand the coverage of its basic medical insurance system and ease the cost of medical services, Health Minister Chen Zhu said Friday.Chen made the remarks while addressing a meeting for the reform of the health care system.The medical expenditure that shouldered by individuals had been cut to 38.2 percent of China's annual overall spending on medical services in 2009, down from 60 percent in 2001, thanks to increasing government funding support for the measure, said Chen.He said the country is striving to bring down the ratio to below 30 percent by the end of the country's 12th five-year plan period (2011-2015).China is steadily pushing towards the implementation of a basic medicine system which aims to ensure affordable access to essential drugs for patients, Chen said.In the areas already covered by basic medicine system, the average price of basic medicine has dropped by around 30 percent, Chen added.He said that the reform of government-run hospitals, which is key to ensure that the masses gain universal access to basic health care services, must be undertaken.In 2011, more measures will be made to restructure the distribution of public hospitals, reform government-run traditional Chinese medical institutions and support building and developing hospitals in county-level regions, Chen said.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.